NCT05071781View on ClinicalTrials.gov

Effect of CRH on Duodenal Markers and Gastric Sensorimotor Function

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
GI Motility Disorder
Interventions
DRUG

Corticotropin-release hormone

intravenous CRH (100 µg)

DRUG

Corticotropin-release hormone

a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)

Trial Locations (1)

3000

I-Hsuan Huang, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER